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ABSTRACT 
Objectives: This study was conducted to evaluate the frequency 
of occurrence and antimicrobial susceptibility of bacterial iso- 
lates collected from patients with skin and soft tissue infec- 
tions (SSTI) in Latin American hospitals, as part of the SENTRY 
Antimicrobial Surveillance Program. The dissemination of 
multidrug-resistant methicillin-resistant Sfaphy/ococcus aureus 
(MDR-MRSA) among the Latin American countries also was 
studied. 
Material and Methods: A total of 885 bacterial isolates were 
analyzed. At the monitoring laboratory, antimicrobial suscepti- 
bility testing utilizing the reference broth microdilution method 
and confirmation of species identification were performed. 
Enterobacteriaceae possibly producing extended-spectrum 
O-lactamases (ESBL) and MDR-MRSA isolates were genotyped 
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by ribotyping using the RiboPrinterTM and by pulsed-field gel 
electrophoresis. 
Results: Sfaphy/ococcus aureus (31%) was the most common 
etiologic agent causing SSTI, followed by Escherichia CO/~ 
(13.4%) and Pseudomonas aeruginosa (11%). Thirty-one per- 
cent of S. aureus isolates were resistant to oxacillin (methicillin). 
The presence of ESBL phenotypes was markedly higher among 
the Klebsiella pneumoniae (35.5%) than E. co/i isolates (10.2%). 
Meropenem was the compound with the highest susceptibil- 
ity rate among the Enterobacteriaceae (100%) and P aeru- 
ginosa (95%) isolates. A great genetic similarity was observed 
among the MDR-MRSA in Latin America. 
Conc/usion: High resistance rates to antimicrobial drugs among 
the most frequent bacterial pathogens were observed in IO 
medical centers in Latin America. This study also demonstrated 
a clonal dissemination of a MDR-MRSA strain in several nations. 
Key Words: antimicrobial resistance, Latin America, skin and 
soft tissue infections, surveillance study 
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The skin serves as an important obstacle to the invasion 
of infectious agents. When skin integrity is physically bra- 
ken intentionally (surgery) or accidentally (trauma), infec- 
tious agents are capable of causing local infection. The 
infection also can reach contiguous structures (soft tissue) 
or disseminate via the blood stream to distant organs. 
The clinical presentation of skin and soft tissue infection 
(SSTI) may vary from mild folliculitis to severe necrotiz- 
ing fascitis. The mode of acquisition also may vary with 
community-acquired SSTI, often preceded by injuries 
resulting from occupational exposure or recreational 
activities, and usually associated with a greater diversity 
of pathogens, whereas hospital-acquired SSTI are gener- 
ally associated with surgical procedures, the development 
of pressure sores, and catheterization. 1 
In spite of the improvement in surgical techniques 
and the use of antimicrobial agents as prophylaxis, sepsis 
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attributable to surgical site infection (SSI) constitutes an 
important cause of postsurgical death.2 Currently, post- 
surgical infections are the third most frequent nosoco- 
mial infection and account for 17% of all nosocomial 
infections reported to the National Nosocomial Infec- 
tions Surveillance (NNIS) System.3 Like all nosocomial 
infections, SSI may prolong the duration of hospitaliza- 
tion and increase morbidity and mortality rates, thereby 
increasing the cost of patient care.4,5 
In addition to microbial factors, a complex interaction 
among host and environmental factors can be responsi- 
ble for acquisition of SSI, including the clinical condition 
of the patient, the ability of the surgeon, the type of 
surgery, and the hospital environment.2,6 Pathogens that 
infect surgical incisions may originate from the patient’s 
microbiota, from the hospital environment, or from health 
care workers. The most frequent source of infection is the 
patient’s endogenous flora. Staphylococcus aureus, coag- 
ulase-negative staphylococci (CONS), and Enterococcus 
spp are the pathogens most frequently isolated from SSI 
in the United States.‘as Latin America has distinct char- 
acteristics compared to North America, such as climatic 
condition and economic situation. These aspects also may 
influence the etiology of the SSI. Previous studies have 
reported a high prevalence of Acinetobacter baumannii 
causing nosocomial pneumonia as well as a higher preva- 
lence of both extended-spectrum B-lactamases (ESBL) 
producing Klebsiella pneumoniae and quinolone-resis- 
tant Escherichia coli in Latin America.9~*o These reports 
have emphasized differences between North America 
and Latin America regarding the etiology and the antimi- 
crobial susceptibility of the pathogens causing infection. 
Antimicrobial surveillance studies such as the SENTRY 
Antimicrobial Surveillance Program, which monitors the 
frequency of occurrence and antimicrobial susceptibility 
of pathogens causing infections worldwide, are impor- 
tant for Latin America. Consequently, data based on the 
reality of the region can originate from and be applied 
to managing of local resources, greatly benefiting the 
treatment of patients and saving the limited financial 
resources in developing countries. 
The objective of this study was to evaluate and report 
the current frequency of occurrence and antimicrobial 
susceptibility of bacterial isolates collected from patients 
with SSTI in Latin American hospitals as part of the SEN- 
TRY Antimicrobial Surveillance Program in 1997-98. 
MATERIAL AND METHODS 
Participant Institutions 
Ten medical institutions in Latin America have partici- 
pated in the SENTRY Antimicrobial Surveillance Program. 
The medical centers were located in nine cities and six 
countries. In 1997, isolates from Argentina, Brazil, Chile, 
Colombia, Mexico, and Uruguay were collected. In 1998, 
nine of ten medical centers were identical to those par- 
ticipating in 1997, but the Uruguayan center was replaced 
by a hospital in Venezuela. The selection of the partici- 
pant medical centers was based on the principle that 
they should be sentinel laboratories in their respective 
regions. 
Bacterial Strains 
The participant medical centers were directed by pro- 
tocol to collect isolates from consecutive patients with 
SSTI.” Because the bacterial samples were taken from 
nonsterile body sites, the participant medical centers also 
were directed to collect only bacterial isolates that were 
clinically responsible for the infection. Isolates from 
patients with community-acquired infection also could 
be collected, if the patient had been hospitalized for treat- 
ment of that infection. A total of 885 bacterial isolates 
were analyzed in this study Each participant laboratory 
contributed approximately 100 isolates (50 isolates per 
year) consecutively collected between April and June in 
1997 and in 1998. A summary description of demographic 
data, such as patient age, gender, ward, hospitalization in 
intensive care unit, and if the infection was community- 
or nosocomial-acquired, also was obtained. All isolates 
were identified at the participating institution by the rou- 
tine methodology in use at each laboratory Upon receipt 
at the University of Iowa (monitoring laboratory), isolates 
were subcultured onto blood agar to ensure viability and 
purity. Confirmation of species identification was per- 
formed with the Vitek (bioMerieux Vitek, St Louis, MO) 
or conventional methods, as required. 
SusceptZbiWy Testing 
At the monitoring laboratory, antimicrobial susceptibility 
testing was performed, and results were interpreted using 
the reference broth microdilution method as described 
by the National Committee for Clinical Laboratory Stan- 
dards (NCCLS).12 Quality control was performed using E. 
coli ATCC 25922, S. aweus ATCC 29213, I? aeruginosa 
ATCC 27853, Enterococcus faecalis ATCC 292 12, Haemo- 
philus infuenzae ATCC 49247, and Streptococcus pneu- 
moniae ATCC 49619. Isolates of K.pneumodae and E. 
coli with increased minimum inhibitory concentrations 
(MICs) (2 2 ug/mL) for ceftazidime or ceftriaxone or 
aztreonam were considered as possible ESBL-producing 
phenotypes, according to NCCLS criteria.13 The ESBL phe- 
notype was confirmed by using ESBL E-test strips (AB 
BIODISK, Solna, Sweden), which evaluate the variation in 
the MIC for ceftazidime when tested in the presence of 
2 ug/mL clavulanic acid. The variations of the MIC for the 
ceftazidime alone and for ceftazidime-clavulanate combi- 
nation were compared. A reduction of the ceftazidime 
MIC of more than two 10% dilutions (> fourfold) in the 
presence of clavulanate indicated ESBL production.14 
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Ant2mtcrobZalAgents 
Antimicrobial agents were obtained from their respec- 
tive manufacturers for testing. These included penicil- 
lins (ampicillin, oxacillin, penicillin, ticarcillin, and 
piperacillin), B-lactamase inhibitor combinations (ticar- 
cillin-clavulanic acid, and piperacillin-tazobactam), 
cephalosporins (cefoxitin, ceftazidiie, ceftriaxone, and 
cefepime), a monobactam (aztreonam), carbapenems 
(imipenem and meropenem), fluoroquinolones 
(ciprofloxacin, levofloxacin, trovafloxacin), aminoglyco- 
sides (amikacin, gentamicin, tobramycin), glycopeptides 
(vancomycin, teicoplanin), and other widely marketed 
compounds, such as chloramphenicol, clindamycin, 
erythromycin, rifampin, tetracycline, and trimethoprim- 
sulfamethoxazole. 
Molecular Methods 
The possible ESBL-producing Enterobacteriaceae isolates 
and multidrug-resistant S. aureus (MDR-MRSA) were 
genotyped by ribotyping, using the RiboPrinterTM Micro 
bial Characterization System (E.I. duPont de Nemours or 
Qualicon, Wilmington, DE), according to the manufac- 
turer’s instructions. The patterns are electronically 
imaged, stored, and compared. Pattern comparisons were 
based on both position and signal intensity Isolates with 
coefficients of similarity greater than 0.9 were consid- 
ered to have the same ribotype profile.15 The possible 
ESBL-producing isolates with indistinguishable ribotype 
profiles also were typed, using pulsed-field gel elec- 
trophoresis (PFGE). The MDR-MRSA isolates were evalu- 
ated by PFGE when isolates with indistinguishable 
ribotype profile persisted in the same medical center in 
the 2 monitored years. The PFGE was performed using 
restriction endonucleases @eI and SnzaI, for Enterobac- 
teriaceae and S. aureus, respectively, as previously 
described.i6 Analysis of PFGE patterns was performed by 
visual inspection of photographs of ethidium bromide- 
stained gels. The isolates were classified as indistin- 
guishable if they had the same bands, and as similar if 
they differed by only one to three bands. Similar patterns 
were grouped under the same DNA type (subtypes), and 
isolates differing by more than three different bands were 
considered to represent distinct DNA types. 
The studies of the ESBL-producing K. pneumoniae 
and E. cob with isoelectric focusing were performed using 
crude B-lactamase extracts prepared by freeze-thaw lysis 
of bacterial cultures grown to exponential phase in tryp- 
tic soy broth. I7 For isoelectric focusing tests, a Multiphore 
II electrophoresis system in ampholine-polyacrylamide 
gels (pH 3.5-9.5 and 5.5-8.5) was used. Gels were run 
according to manufacturer’s instructions (Pharmacia 
Biotech, Piscataway, NJ) and stained with 0.5 mM Cefinase 
2 (Becton Dickinson Microbiology Systems, Cockeysville, 
MD).” Preparations of TEM-1, TEM-4, SHV-1, SHV-3, and 
SHV-5 enzymes were included as standards in each gel. l9 
The B-lactamase activity was measured by monitoring the 
rate of hydrolysis of 0.5 mM Cefmase 2 as the substrate. 
RESULTS 
Pathogen Frequency of Occurrence 
During the study period a total of 885 bacterial SSTl iso- 
lates were reported by Latin American centers. Accord- 
ing to the demographic data, 65.6% of the total number 
of pathogens causing SSTI were isolated from patients 
with nosocomial infections; 19.2% were from patients 
with community-acquired infection. The mode of acqui- 
sition of 15.0% of SSTI could not be classitied. The major- 
ity of pathogens were isolated from adult patients 
(93.3%). Table 1 summarizes the 10 most frequently 
encountered pathogens causing SST1 in Latin America 
during the years of 1997 and 1998. The overall rank order 
was based on the total number of isolates of each species 
collected over both years. Gram-negative bacilli were 
Table 1. Rank Order of Skin and Soft Tissue Infection Pathogens Occurring in 
10 Latin America Medical Centers Comparing 1997 and 1998 Samples* 
Number of Organisms Tested (%) 
Rank Order Organisms 
S. aureus 
E. coli 
I? aeruginosa 
Enterococcus spp 
Klebsiella spp 
Enterobacter spp 
Coagulase-negative staphylococci 
Acinetobacter spp 
Proteus spp 
Citrobacter spp 
S. marcescens 
Other species+ 
1997 1998 Total 
133 (28.3) 141 (34.0) 275 (31 .O) 
60 (12.8) 
58 (12.3) 
37 (7.9) 
39 (8.3) 
37 (7.9) 
22 (4.7) 
26 (5.5) 
17 (3.6) 
10 (2.1) 
10 (2.1) 
21 (4.5) 
59 ii4.2j ii9ii3.4j 
39 (9.4) 97 (11 .O) 
41 (9.9) 78 (8.8j 
31 (7.5) 70 17.9) 
8 
9 
10 
11 
21 (5ij 58 i6.6j 
24 (5.8) 46 (5.2) 
16 (3.8) 42 (4.7) 
18 (4.3) 35 (3.9) 
4 (1 .O) 14 (1.6) 
4 (1.0) 14 (1.6) 
17 (4.1) 38 f4.3) 
*SENTRY Antimicrobial Surveillance Program; 885 total strains. 
+lncludes isolates from seven different species in 1997 and 12 species in 1998. 
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Table 2. Antimicrobial Activity of Selected Antimicrobial Agents Tested against Six Pathogen Groups from 
Skin and Soft Tissue Infections in Hospitals in Latin America, 1997 (470 Strains) and 1998 (415 Strains)* 
7 997 M/C Results bg/mL) 1998 M/C Results (@ml) 
Organism (Number Tested, 199 7/l 998) 50% 90% % Resistant+ 50% 90% % Resistantf 
Antimicrobial Agent 
E. co/i (60/59) 
Piperacillin 
Ticarcillin 
Piperacillin-tazobactam 
Ticarcillin-clavulanate 
Cefoxitin 
Ceftriaxone 
Ceftazidime 
Cefepime 
Aztreonam 
lmipenem 
Meropenem 
Ciprofloxacin 
Levofloxacin 
Trovafloxacin 
Amikacin 
Gentamicin 
Tobramycin 
Tetracycline 
Trimethoorim-sulfamethoxazole 
Klebsiella spp (39131) 
Piperacillin 
Ticarcillin 
Piperacillin-tazobactam 
Ticarcillin-clavulanate 
Cefoxitin 
Ceftriaxone 
Ceftazidime 
Cefepime 
Aztreonam 
lmipenem 
Meropenem 
Ciprofloxacin 
Levofloxacin 
Trovafloxacin 
Amikacin 
Gentamicin 
Tobramycin 
Tetracycline 
Trimethoprim-sulfamethoxazole 
Enterobacter spp (37121) 
Piperacillin 
Ticarcillin 
Piperacillin-tazobactam 
Ticarcillin-clavulanate 
Cefoxitin 
Ceftriaxone 
Ceftazidime 
Cefepime 
Aztreonam 
lmipenem 
Meropenem 
Ciprofloxacin 
Levofloxacin 
Trovafloxacin 
Amikacin 
Gentamicin 
Tobramycin 
Tetracycline 
Trimethoprim-sulfamethoxazole 
>I28 >128 60.0 
>128 >128 65.0 
4 >64 16.7 
32 >I28 35.0 
8 >32 11.6 
SO.25 2 8.3 (11.7)f 
0.25 16 6.7 (15.0)* 
go.12 2 5.0 
SO.12 8 8.3 (15.0)~ 
0.25 0.5 0.0 
10.06 SO.06 0.0 
0.03 >2 40.0 
SO.5 >4 35.0 
0.06 >4 40.0 
4 16 3.3 
2 >16 26.7 
2 >I6 16.6 
>8 >8 56.7 
>l >I 56.7 
64 >128 48.7 
>128 >I 28 87.2 
8 >64 38.5 
8 >I28 38.5 
4 16 2.6 
20.25 >32 17.9 (43.6)$ 
0.5 >I6 30.8 (43.6)* 
SO.12 >I6 15.4 
SO.12 >I6 30.8 (43.6)t 
0.25 2 0.0 
SO.06 0.25 0.0 
0.06 2 7.7 
SO.5 4 2.6 
0.25 4 10.3 
8 32 10.3 
2 >16 35.9 
2 >16 43.6 
S4 >8 30.8 
SO.5 >I 38.5 
8 >128 32.4 
64 >128 37.8 
8 >64 24.3 
64 >128 40.5 
>32 >32 83.8 
1 >32 24.3 
1 >16 29.7 
0.5 16 8.1 
0.25 >I6 37.8 
0.5 2 0.0 
0.12 0.5 0.0 
0.06 >2 16.2 
SO.5 >4 10.8 
0.25 >4 16.2 
2 16 5.4 
1 >16 13.5 
1 >I6 18.9 
S4 >8 24.3 
10.5 >1 16.2 
>128 
>128 
2 
16 
4 
SO.25 
0.25 
go.12 
SO.12 
0.12 
SO.06 
SO.01 5 
10.5 
10.03 
2 
>8 
SO.5 
>I28 
>128 
4 
16 
4 
SO.25 
0.25 
co.12 
SO.12 
0.25 
SO.06 
0.03 
SO.5 
0.06 
2 
0.5 
54 
SO.5 
4 
64 
4 
8 
>32 
0.5 
0.5 
SO.12 
10.12 
0.5 
SO.06 
0.03 
SO.5 
0.06 
2 
0.5 
54 
10.5 
>128 
>128 
64 
>I28 
32 
0.5 
2 
0.25 
SO.06 
>2 
>4 
>4 
8 
>I6 
16 
>8 
>l 
>128 
>I 28 
>64 
>I28 
>32 
>32 
>16 
>16 
>I6 
0.12 
>2 
>4 
4 
>32 
>I6 
>I6 
>8 
>I 
>I28 
>128 
>64 
>I28 
>32 
>32 
>16 
8 
>I6 
$0.06 
2 
2 
4 
8 
8 
16 
>8 
>I 
55.9 
61 .O 
8.5 
13.6 
13.6 
3.4 (8.5)t 
3.4 (10.2)’ 
3.4 
3.4 (6.8)* 
0.0 
0.0 
22.0 
18.6 
22.0 
1.7 
11.9 
6.8 
54.2 
45.8 
51.6 
97.1 
25.8 
38.8 
16.1 
25.8 (35.5)$ 
22.6 (35.5)* 
12.9 
22.6 (29.0)* 
0.0 
0.0 
22.6 
12.9 
19.4 
12.9 
32.3 
35.5 
45.2 
32.3 
33.3 
47.6 
14.3 
38.0 
76.2 
23.8 
28.6 
4.8 
28.6 
0.0 
0.0 
9.5 
9.5 
14.3 
4.8 
9.5 
19.0 
19.0 
28.6 
*Only the six most frequent pathogens (79% of all reported strains) were tabulated. 
‘Resistance rate determined by NCCLS (1998) interpretive criteria or as follows: trovafloxacin susceptible at 5 1 ug/mL and resistant at 2 4 pg/mL. 
*Percentage in parenthesis indicates the strains having elevated MlCs consistent with an ESBL phenotype (NCCLS, 1998). 
Tndicates % of strains resistant to synergistic interactions with cell-wall active drugs when tested against enterococci. 
npercentage in parenthesis indicates the strains resistant to streptomycin synergistic killing. 
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Table 2. Antimicrobial Activity of Selected Antimicrobial Agents Tested against Six Pathogen Groups from 
Skin and Soft Tissue infections in Hospitals in Latin America, 1997 (470 Strains) and 1998 (415 Strains)* (continued) 
Organism (Number Tested, 1997/1998) 
1997 MIC Results @g/mL) 1998 M/C Results @g/ml) 
50% 90% % Resistant+ 50% 90% % Resistant+ 
Antimicrobial Agent 
I? aeruginosa (58/39) 
Piperacillin 
Ticarcillin 
Piperacillin-tazobactam 
Ticarcillin-clavulanate 
Cefoxitin 
Ceftriaxone 
Ceftazidime 
Cefepime 
Aztreonam 
lmipenem 
Meropenem 
Ciprofloxacin 
Levofloxacin 
Trovafloxacin 
Amikacin 
Gentamicin 
Tobramycin 
Tetracycline 
Trimethoprim-sulfamethoxazole 
S. aufeus (133/l 41) 
Penicillin 
Oxacillin 
Cefazolin 
Ceftriaxone 
Cefepime 
lmipenem 
Ciprofloxacin 
Trovafloxacin 
Gentamicin 
Erythromycin 
Clindamycin 
Tetracycline 
Chloramphenicol 
Rifampin 
Teicoplanin 
Vancomycin 
Nitrofurantoin 
Trimethoprim-sulfamethoxazole 
Enterococcus spp (37141) 
Ampicillin 
Oxacillin 
Penicillin 
lmipenem 
Ciprofloxacin 
Trovafloxacin 
Gentamicine 
Etythromycin 
Clindamycin 
Tetracycline 
Chloramphenicol 
Rifampin 
Teicoplanin 
Vancomycin 
Nitrofurantoin 
Trimethoprim-sulfamethoxazole 
8 128 20.6 
32 >128 31 .o 
8 >64 15.5 
32 >128 29.3 
>32 >32 100.0 
>32 >32 70.7 
4 >I6 22.4 
4 >16 22.8 
8 >16 22.4 
2 >a 17.2 
0.5 >8 13.8 
0.25 >2 27.6 
1 >4 27.6 
1 >4 36.2 
4 >32 19.0 
2 >16 24.1 
1 >16 22.4 
>a >a 98.3 
>I >l 98.3 
32 >32 96.2 
1 >8 31.6 
52 216 31.6 
4 >32 31.6 
4 >16 31.6 
0.12 >8 31.6 
0.5 >2 29.3 
0.06 2 6.8 
0.5 >16 30.8 
1 >a 46.6 
0.25 >a 27.1 
54 >a 23.3 
a >I6 20.3 
10.015 2 6.0 
0.5 2 0.0 
0.5 1 0.0 
532 132 4.5 
50.5 >1 17.3 
1 a 2.7 
>a >a 100.0 
2 8 5.4 
1 8 8.1 
2 >2 48.6 
1 >4 35.1 
1500 >lOOO 16.2 (24.3)” 
8 .a 89.2 
>8 >8 100.0 
>a >a 59.5 
8 >16 16.2 
>2 >2 73.0 
0.25 1 0.0 
1 2 0.0 
232 64 a.1 
SO.5 >l 29.7 
16 >128 33.3 
64 >128 43.5 
16 >64 25.6 
64 >128 48.7 
>32 >32 100.0 
>32 >32 84.6 
a >16 33.3 
a >I6 17.9 
16 >16 41 .o 
2 >a 10.3 
1 a 5.1 
0.5 >2 35.9 
2 >4 30.8 
1 >4 38.5 
8 >32 15.4 
4 >I6 30.8 
1 >16 33.4 
>8 >8 94.9 
>l >l 100.0 
32 >32 96.5 
1 >8 30.5 
52 >16 30.5 
4 >32 30.5 
4 >16 30.5 
SO.06 >8 30.5 
0.5 >2 29.1 
SO.03 1 2.8 
0.5 >I6 30.5 
0.5 >a 39.7 
0.25 >8 29.1 
14 >8 25.5 
16 >I6 25.5 
10.25 2 7.1 
1 2 0.7 
1 1 0.0 
532 132 0.0 
10.5 >1 22.7 
1 
>8 
4 
2 
A.25 
<500 
2 
>8 
>a 
a 
>2 
0.25 
2 
532 
SO.5 
4 4.9 
>a 100.0 
16 12.1 
4 2.4 
>2 24.4 
>4 14.6 
1500 9.8 (31.7)” 
>8 80.5 
>8 100.0 
>8 63.4 
>I6 26.8 
>2 75.6 
0.5 0.0 
2 2.4 
532 2.4 
>l 19.5 
*Only the six most frequent pathogens (79% of all reported strains) were tabulated. 
+Resistance rate determined by NCCLS (1998) interpretive criteria or as follows: trovafloxacin susceptible at 5 1 pg/mL and resistant at 2 4 pg/mL. 
*Percentage in parenthesis indicates the strains having elevated MlCs consistent with an ESBL phenotype (NCCLS, 1998). 
“Indicates % of strains resistant to synergistic interactions with cell-wall active drugs when tested 
IPercentage in parenthesis indicates the strains resistant to streptomycin synergistic killing. 
against enterococci. 
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associated with 5 1% of the SSTIs, and gram-positive cocci 
caused 45% of the infections. Staphylococcus auwus was 
the most frequently isolated pathogen, causing 31% of 
the SSTI, followed by E. coli (13.4%) and I? aeruginosa 
(11%). The distribution of the five most frequently isolated 
pathogens was similar among the distinct Latin Ameri- 
can centers. 
Antimicrobial Susceptibility Patterns 
The in vitro antimicrobial susceptibility results of the 
most frequently isolated pathogens causing SSTIs are 
shown in Table 2. Meropenem and imipenem were the 
only antimicrobial agents capable of inhibiting growth 
of 100.0% of E. colz’ isolates. Penicillins alone demon- 
strated poor activity (MIC,, > I6 yg/mL). Piperacillin- 
tazobactam was the penicillin-B-lactamase inhibitor 
combination with the highest in vitro activity (MIC,,s, 
2-4 ug/mL) and susceptibility rates (83386.4%) in both 
years. Although aztreonam and broad-spectrum 
cephalosporins had demonstrated excellent in vitro activ- 
ity, 15.0% and 10.2% of the E. colz’ isolates collected in 
1997 and 1998 respectively could be considered as ESBL 
producers based on the NCCLS criteria.13 The resistance 
to fluoroquinolones was markedly high among the iso- 
lates evaluated. Of the aminoglycosides tested, amikacin 
was the most active against E. coli. 
Meropenem and imipenem were also the most active 
of the agents tested against the Klebsiella spp isolates. 
The broad-spectrum cephalosporins demonstrated excel- 
lent in vitro activity against these isolates (MIC5, range, 
5 0.12-0.25 ug/mL); however, elevated rates of resistance 
were observed. In 1997, the highest resistance rate was 
exhibited by ceftazidime (30.8%) followed by ceftriax- 
one (17.9%) and cefepime (15.8%), whereas in 1998 cef- 
triaxone showed the highest resistance rate (25.8%) and 
cefepime remained the most active cephalosporin (12.9% 
resistance). In spite of the good in vitro activity generally 
exhibited by the fluoroquinolones, an important increase 
in the resistance to this class of antimicrobial agents was 
observed in 1998. Only 7.7% of Klebsiella spp isolates 
were resistant to ciprofloxacin in 1997, whereas threefold 
(22.6%) more were considered resistant the following 
year. 
Among the B-lactams tested against the Entero- 
batter spp, the carbapenems and cefepime were the 
most potent antimicrobial agents (susceptibility > 95% 
in 1998). Resistance to third-generation cephalosporins 
varied from 23.8% (ceftriaxone in 1998) to 29.7% 
(ceftazidime in 1997). The activities of the 8-lactamase 
inhibitor combinations also were limited. Amikacin 
showed excellent activity (MI& = 2 ug/mL) with low 
resistance rates (4.8-5.4%). However, resistance to other 
aminoglycosides was fourfold greater than to amikacin. 
Resistance rates to fluoroquinolones varied from 9.5 to 
16.2%. 
The most active compounds against I! aeruginosa 
strains were meropenem, piperacillin-tazobactam, and 
imipenem. Piperacillin and piperacillin-tazobactam 
demonstrated similar in vitro activity, but piperacillin- 
tazobactam exhibited higher susceptibility. Resistance to 
nearly all tested antimicrobial drugs increased from 1997 
to 1998, except for cefepime, carbapenems, and amikacin. 
Ceftazidime and cefepime displayed the same in vitro 
activities (MICs, = 4 ug/mL) and similar resistance rates 
in 1997 (22.4% and 22.8%, respectively). However, in 1998 
resistance to cefepime (17.9%) was lower than that of 
ceftazidime (33.3%). Ciprofloxacin was the most active 
quinolone tested. 
Approximately 31% of the S. aureus isolates tested 
showed resistance to oxacillin. Only vancomycin inhib 
ited 100% of the isolates at NCCLS susceptible MIC break- 
point concentrations. Although teicoplanin displayed in 
vitro activity similar to that of vancomycin, in 1998 an iso- 
late with a reproducible teicoplanin MIC of 16 ug/mL 
was found. This isolate also had a relatively high MIC for 
vancomycin (4 ug/mL). Although reduced susceptibility 
to vancomycin in S. aureus has been described, this phe- 
nomenon is still a rare eventzO The resistance to non-B- 
lactam compounds also was strongly related to oxacillin 
resistance. The resistance rates to clindamycin and gen- 
tamicin were nearly 30%. Ciprofloxacin demonstrated 
identical activity (MIC,, = 0.5 ug/mL) and resistance rates 
(nearly 29%) in both years, a rate closely approximating 
that seen for oxacillin. Trovafloxacin showed to be the 
most active (MICs,, = 0.06 and I 0.03 ug/mL) quinolone 
tested against S. aureus isolates. In spite of being a potent 
agent (MIC,,, _ < 0.5 ug/mL), trimethoprim-sulfamethoxa- 
zole resistance rate among S. aureus strains was above 
20.0%. 
Ampicillin showed excellent activity against Entero- 
coccus spp (MICso = 1 @mL, >97% susceptibility). The 
high activity of this compound may be explained by a 
high percentage (87.8%) of E. faecalis among the ente- 
rococci isolates tested. Teicoplanin was the most active 
drug WC,, = 0.25 kg/mL). Although resistance to van- 
comycin had been recently described in Latin America,21 
vancomycin and teicoplanin inhibited all Enterococcus 
spp isolates. Among the newest fluoroquinolones, 
trovafloxacin was the most active compound, with resis- 
tance rates of only 14.6% in 1998. The detection of high- 
level resistance (HLR) to aminoglycosides is important 
because it can affect combination enterococcal therapy. 
This degree of resistance predicts resistance to synergism 
between cell-wall active agents and the aminoglycosidesz2 
In 1998,9.8% and 31.7% of Enterococcus spp demon- 
strated HLR for gentamicin and streptomycin, respectively 
Characterization of ESBL-Producing Enteric Bacilli 
Among the isolates selected as possible ESBL producers 
based on the NCCLS criteria, 12 enteric bacilli (4 E. coli 
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and 8 K. pneumortiae) isolated in the same center 
demonstrating similar phenotypes of co-resistance were 
selected for further evaluation (Table 3).13 Only 7 of 12 
enteric bacilli were confirmed as ESBL producers using 
the ESBL E-test strip. Bacterial strains with similar phe- 
notype isolated in the same institution were ribotyped by 
the RiboPrinterTM.15 Whereas the E. coli isolates from 
medical center 045 had distinct ribotypes, both K.pneu- 
moniae strains had indistinguishable ribotype (874-8) 
and PFGE profiles (pattern C). The E-test did not confiim 
that these K.pneumoniae isolates were ESBL producers, 
and their antibiograms for cephalosporins suggested the 
presence of an AmpC cephalosporinase.‘9 The three K. 
pneumoniae strains isolated from medical center 040 
showed different ribotypes; however, enzymes, for which 
isoelectric points (pIs) were 5.4, 6.8, and 7.6, were 
detected in all three isolates. 
Multidrug-Resistant Staplylococcus aureus 
Methicillin-resistant S. aureus isolates that also were resis- 
tant to at least four of eight additional antimicrobial 
classes tested (aminoglycosides, chloramphenicol, clin- 
damycin, erythromycin, fluoroquinolones, rifampin, 
trimethoprim-sulfamethoxazole, and tetracycline) were 
defined as MDR-MRSA. The qualifying strains were fur- 
ther evaluated by ribotyping and PFGE. Of 274 S. aureus 
isolates, 49 (26 from 1997 and 23 from 1998) were 
included in this study group (Table 4). All monitored cen- 
ters in Brazil and Chile had MDR-MRSA collected in both 
years; MDR-MRSA also was isolated in Uruguay in 1997 
and in one Argentinean hospital in 1998. Eleven ribotype 
profiles were observed among the 49 MDR-MRSA iso- 
lates, but 71% of these strains were grouped in only two 
ribotype profiles: 893-5 (21 isolates) and 1844 (14 iso- 
lates). In addition, ribotype 893-5 was highly correlated 
with PFGE pattern A, whereas the ribotype 184-4 corre- 
lated with PFGE pattern C. Isolates with ribotype 184-4 
and PFGE pattern C were isolated only in Chile (both 
hospitals), whereas isolates with ribotype 893-5 and PFGE 
pattern A were observed in Argentina in 1998, and in 
Brazil and Chile in both years. Ten PFGE subtypes were 
observed among the 27 MDR-MRSA isolates with PFGE 
pattern A. Four MDR-MRSA strains with ribotype 901-2 
and one strain with ribotype 184-5 also demonstrated 
the PFGE pattern A. The genomic variability observed in 
the PFGE pattern C was less than that observed in the pat- 
tern A, and only five PFGE subtypes were detected among 
the 14 MDR-MRSA strains with pattern C. 
DISCUSSION 
Staplylococcus aureus was the most frequently occur- 
ring pathogen causing SSTI in Latin America. S. aureuS iso- 
lates frequently have been reported as an etiologic agent 
of community- and hospital-acquired SSTI.’ The high num- 
ber of nosocomial infections could be one of the reasons 
for the higher prevalence of gram-negative bacilli 
reported. The Enterococcus genus has been frequently 
reported as the etiologic agent of urinary, blood stream, 
and surgical site infections in North American medical 
centers, but it has been less common in Latin Amer- 
ica.‘0,23-25 However, this study demonstrated that the 
prevalence of enterococci as a cause of SSTI has increased 
in this geographic area, although they remain highly sus- 
ceptible to ampicillin and glycopeptides. 
The data presented show E. coli and Klebsiella spp 
as important pathogens causing SSTI. The most impor- 
tant emerging resistance mechanism among these species 
is ESBL production. Approximately 15% of E. toll and 
Table 3. Phenotypes and Locations of 12 Enteric Bacilli with Extended-Spectrum P-Lactamases* 
Organism 
(n Tested) M/C 0.W-G 
Medical Center/ 
/so/ate Number 
ESBL Co-Resistance 
Ceftazidime Ceftriaxone Cefepime Cefoxitin Test? Patterns* Ribotype 
PFGE 
Profile 
Isoelectric 
Focusing (p/J 
E. co/i (n = 4) 
040(n=ll2) 16 >32 >16 >32 + A,G,To,F,Tc,T-S,N ND ND ND 
042 (n = 462) 4 >32 >16 a + G,To,F,Tc,T-S ND ND ND 
045 (n = 224) >16 8 8 16 - To,F,Tc,T-S 253-7 ND ND 
(n = 229) >16 32 16 >32 - To,F,Tc,T-S 253-5 ND ND 
K. pneumoniae (n = 8) 
040 (n = 60) >16 >32 16 4 + G,To,Tc,T-S 868-8 ND 5.4, 6.8, 7.6 
I” 1:;; 
>16 >32 >16 4 f G,To,F,Tc,T-S,N 614-l” ND 5.4, 6.8, 7.6 
(:: = 81) 
>I6 >32 >16 8 + G,To,F,Tc,T-S,N 623-4” ND 5.4, 6.5, 6.8, 7.6, 7.9 
2 16 4 32 - A,G,To,F,Tc,T-S,N ND ND ND 
045 (n = 222) a 16 0.25 32 - - 874-8” Pattern C Not detected 
I” 1 ;;;I 
8 16 0.25 >32 - - 874-8” Pattern C Not detected 
046(:=16) 
>I6 >32 8 >32 + A,G,To,F,Tc,T-S,N ND ND ND 
8 >32 >I6 4 + G,To ND ND ND 
*SENTRY Antimicrobial Surveillance Program, 1998. 
+E-test ESBL strip test for inhibitor (ciavulanate) sensitive enzymes using a ceftazidime substrate only. 
*Indicates resistances (NCCLS, 1999) as follows: A = amikacin, G = gentamicin, To = tobramycin, F = fluoroquinolones, Tc z tetracyclines, T-S = trimethoprim- 
sulfamethoxazole, and N = nitrofurantoin. 
%ibotyping (Riboprint by Qualicon) for phenotypically similar isolates at the same institution, ND = not determined. 
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Table 4. Patterns of Multidrug-Resistant S. aureus Isolates Causing Skin and Soft Tissue 
Infections in 10 Latin American Medical Centers between 1997 and 1998 
Number of Strains 
Country Medical Center 
Argentina 
040 
Brazil 
Ribotype Profiles 1997 (n = 26) 7998 (n = 23) PFGE Patterns* (n) 1997/1998 
893-5 - 2 A, (2) 
041 893-5 2 5 
901-2 - 3 
901-4 - 1 
046 184-5 1 - 
893-5 3 2 
048 893-5 2 2 
901-2 - 2 
902-3 - I 
A, Cl), %V) / A, 6% A, (2), A,(l) 
A, M, D (1) 
Not determined 
A,(l) 
A,(l),A,(l),A,(l)/A,(2) 
A,(l),A,(l)/A,(l),B(l) 
A, (1)s A, (1) 
Not determined 
Chile 
042 
043 
Uruguay 
047 
184-4 4 2 (2) 
893-5 
q 
2 
(a c, U)! c, (1) / c, 
- 
895-7 1 
A,, (2) 
900-l 
902-8 
184-4 
893-5 
903-8 
184-5 
317-2 
1 
- 
8 
- 
- 
01 
01 
- 
1 
- 
1 
1 
- 
- 
Not determined 
Not determined 
Not determined 
c, (I), C, Cl), 
A,, (1) 
C, (6) 
Not determined 
E 
Not determined 
*Subscript numbers represented subtypes of the PFGE pattern A or C. 
35.5% of Klebsiellu spp demonstrated a phenotype con- 
sistent with ESBL production, confirming high rates of 
ESBL-producing isolates in Latin America, as reported pre- 
viously.24,26 The ESBL-producing E. coli and Klebsiella spp 
isolates demonstrated an alarming degree of cross-resis- 
tance. In fact, the only effective therapeutic agents against 
these isolates are the carbapenems. The ESBL-producing 
Enterobacteriaceae evaluated exhibited distinct chromo- 
somal genotypes but displayed a related p1 profile. Since 
ESBL production is plasmid-mediated, bacterial isolates 
with different chromosomal DNA can share the same 
plasmids, and, consequently, produce the same B-lacta- 
mases. The ESBLencoding plasmids also may confer resis- 
tance to different classes of antimicrobial drugs.*’ The p1 
5.4 and 7.6 found in the tested isolates could correspond 
to TEM-1 and WV-1 enzymes (non-ESBL), which are com- 
monly observed in Enterobacteriaceae, but a range of 
ESBLs can have exactly the same pIs.iv The band with p1 
7.9 may correspond to CTX-ase-M-2, an ESBL already 
described among Salmonella isolates from Argentina.‘9,28 
This finding suggests the possible transmission of the 
plasmid that encodes CTX-ase-M-2 to another bacterial 
species. Further evaluations are necessary for detailed 
characterization of the ESBL-producing isolates. 
An epidemic Brazilian strain (strain SP), which was 
previously reported as responsible for dissemination of 
methicillin resistance in Brazil, also was included as a 
control in the MDR-MRSA analysis.29 The strain SP pre- 
sented as ribotype profile 893-5 and PFGE pattern A (sub 
type A,). The MDR-MRSA isolates recently collected from 
Brazilian hospitals exhibited indistinguishable chromo- 
somal DNA to strain Sl? In addition, MDR-MRSA collected 
in Argentina and Chile displayed a similarity to strain Sl? 
These findings indicate that strain SP also could be 
involved in the dissemination of MDR-MRSA in other Latin 
American countries (Figure 1). They also strongly sug- 
gest occurrence of clonal dissemination of MDR-MRSA 
in Latin America; however, further epidemiologic studies 
are necessary to prove this link. 
Surveillance studies, such as the SENTRY Antimicro- 
bial Surveillance Program, have contributed to an 
expanded understanding of the epidemiology of bacter- 
ial resistance in Latin America, as well as the frequency 
of pathogen occurrence for commonly observed infec- 
tions. This program is providing important information for 
guiding empirical antimicrobial therapy and the imple- 
mentation of antimicrobial resistance control measures in 
distinct geographic areas. 
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Figure 1. Selected PFGE patterns of the multidrug-resistant S. aureus 
(MD-MRSA) isolated in Latin America that exhibited ribotype 893-5. 
Lane 1, 6, and 13, strain SP (PFGE pattern A,); lane 2, isolate 40-66 
(oattern A): lane 3. isolate 40-82 (oattern A,): lane 4, isolate 42-226 
[pattern A,J; lane 5: isolate 43-415 ‘(pattern A:& lane 7, isolate 41-444 
(pattern A,); lane 8, isolate 41-510 (pattern AJ lane 9, isolate 46-474 
(pattern A,); lane 10, isolate 46-l 0 (pattern A,); lane 11, isolate 48-119 
(pattern A,); and lane 12, isolate 48-202 (pattern A,). 
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